Chimerix to Report Second Quarter 2021 Financial Results and Provide an Operational Update on August 5, 2021

Rhea-AI Summary

Chimerix (NASDAQ:CMRX) has scheduled a conference call for August 5, 2021, at 8:30 a.m. ET to discuss its Q2 2021 financial results and operational updates. The company recently received FDA approval for TEMBEXA® to treat smallpox and is advancing its clinical programs, including ONC201 for recurrent H3 K27M-mutant glioma and dociparstat sodium (DSTAT) for acute myeloid leukemia. The press release highlights the ongoing clinical trials and the importance of upcoming reviews for ONC201.

Positive

• FDA approval for TEMBEXA® for smallpox treatment.
• Advancement in clinical-stage programs ONC201 and DSTAT.
• Ongoing registrational clinical program for ONC201 with independent review expected later in 2021.

Negative

• Risks that Phase 2 trial data for ONC201 may not support regulatory approval.
• Reliance on a sole source third-party manufacturer for drug supply.
• Potential delays in procurement contracts for TEMBEXA.

DURHAM, N.C., July 29, 2021 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, today announced that it will host a live conference call and audio webcast on Thursday, August 5, 2021 at 8:30 a.m. ET to report financial results for the second quarter ended June 30, 2021, and to provide an operational update.

To access the live conference call, please dial (877) 354-4056 (domestic) or (678) 809-1043 (international) at least five minutes prior to the start time, and refer to conference ID 6658827. A live audio webcast of the call will also be available on the Investors’ section of the Company's website, www.chimerix.com. An archived webcast will be available on the Chimerix website approximately two hours after the event.

About Chimerix

Chimerix is a development-stage biopharmaceutical company dedicated to accelerating the advancement of innovative medicines that make a meaningful impact in the lives of patients living with cancer and other serious diseases. In June 2021, the U.S. Food and Drug Administration granted approval of TEMBEXA® for the treatment of smallpox as a medical countermeasure. The Company has two other advanced clinical-stage development programs, ONC201 and dociparstat sodium (DSTAT). ONC201 is currently in a registrational clinical program for recurrent H3 K27M-mutant glioma and a blinded independent central review is expected later in 2021. DSTAT is in development as a potential first-line therapy in acute myeloid leukemia.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks and uncertainties that could cause actual results to differ materially from those projected. Forward-looking statements include those relating to, among other things, Chimerix’s growth and development. Among the factors and risks that could cause actual results to differ materially from those indicated in the forward-looking statements are risks that the current Phase 2 clinical trial data for ONC201 will not support accelerated, or any, regulatory approval; the anticipated benefits of the acquisition of Oncoceutics may not be realized; risks that Chimerix will not obtain a procurement contract for TEMBEXA in smallpox in a timely manner or at all; Chimerix’s reliance on a sole source third-party manufacturer for drug supply; risks that ongoing or future trials may not be successful or replicate previous trial results, or may not be predictive of real-world results or of results in subsequent trials; risks and uncertainties relating to competitive products and technological changes that may limit demand for our drugs; risks that our drugs may be precluded from commercialization by the proprietary rights of third parties; and additional risks set forth in the Company's filings with the Securities and Exchange Commission. These forward-looking statements represent the Company's judgment as of the date of this release. The Company disclaims, however, any intent or obligation to update these forward-looking statements.

CONTACTS:

Michelle LaSpaluto
919 972-7115
ir@chimerix.com

Will O’Connor
Stern Investor Relations
212-362-1200
will@sternir.com

FAQ

What are the upcoming events for Chimerix in August 2021?

Chimerix will host a conference call on August 5, 2021, to discuss its Q2 2021 financial results and operational updates.

What is the significance of TEMBEXA® approval for Chimerix?

The FDA approved TEMBEXA® as a treatment for smallpox, marking a significant milestone in Chimerix's development of medical countermeasures.

What are the risks involved with Chimerix's clinical trials?

Chimerix faces risks that the data from the ongoing Phase 2 trials for ONC201 may not lead to regulatory approval and potential delays in drug supply.

When can investors expect updates on ONC201?

A blinded independent central review for ONC201 is expected later in 2021, which will provide critical data for its registrational clinical program.